Login
Drug response
About us
FAQ
Insights
New
Pathway
New
Contact us
^
Login
Gene family
(
)
(
)
(
)
See all results for "
"
My recent searches
No previous search
Home
>
Drug Response
Veri cancer hierarchy
PD-L1 expression
PD-L1 expression
Non Small Cell Lung Cancer
NSCLC
durvalumab
Sensitive: A1 - Approval
AstraZeneca Press Release - 1 day
Sensitive: A1 - Approval
AstraZeneca Press Release - 1 day
No biomarker
No biomarker
Urothelial Cancer
Urothelial Cancer
padeliporfin
Sensitive: B - Late Trials
Cision - 1 day
Sensitive: B - Late Trials
Cision - 1 day
ALK positive
ALK positive
Non-Hodgkin’s Lymphoma
NHL
crizotinib
Sensitive: A1 - Approval
FDA - 2 days
Sensitive: A1 - Approval
FDA - 2 days
No biomarker
No biomarker
Chronic Lymphocytic Leukemia
CLL
rituximab + ibrutinib
Sensitive: A1 - Approval
Cision - 3 days
Sensitive: A1 - Approval
Cision - 3 days
No biomarker
No biomarker
Non Small Cell Lung Cancer
NSCLC
tislelizumab
Sensitive: A1 - Approval
BeiGene Press Release - 3 days
Sensitive: A1 - Approval
BeiGene Press Release - 3 days
No biomarker
No biomarker
Sarcoma
Sarcoma
INBRX-109
Sensitive: B - Late Trials
Inhibrx Press Release - 3 days
Sensitive: B - Late Trials
Inhibrx Press Release - 3 days
EGFR exon 19 deletion
EGFR exon 19 deletion
Non Small Cell Lung Cancer
NSCLC
afatinib
Sensitive: A1 - Approval
J Cancer Res Clin Oncol - 4 days
Sensitive: A1 - Approval
J Cancer Res Clin Oncol - 4 days
HER-2 positive
HER-2 positive
HER2 Positive Breast Cancer
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: A1 - Approval
J Oncol Pharm Pract - 4 days
Sensitive: A1 - Approval
J Oncol Pharm Pract - 4 days
No biomarker
No biomarker
Acute Myelogenous Leukemia
AML
azacitidine oral
Sensitive: A1 - Approval
Cision - 4 days
Sensitive: A1 - Approval
Cision - 4 days
TMB-H
TMB-H
Non Small Cell Lung Cancer
NSCLC
nivolumab
Sensitive: A2 - Guideline
IASLC-WCLC 2020 - 4 days
Sensitive: A2 - Guideline
IASLC-WCLC 2020 - 4 days
EGFR L858R
EGFR L858R
Non Small Cell Lung Cancer
NSCLC
icotinib
Sensitive: B - Late Trials
IASLC-WCLC 2021 - 4 days
Sensitive: B - Late Trials
IASLC-WCLC 2021 - 4 days
EGFR exon 19 deletion
EGFR exon 19 deletion
Non Small Cell Lung Cancer
NSCLC
icotinib
Sensitive: B - Late Trials
IASLC-WCLC 2021 - 4 days
Sensitive: B - Late Trials
IASLC-WCLC 2021 - 4 days
EGFR mutation
EGFR mutation
Lung Cancer
Lung Cancer
Tyrosine kinase inhib
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
MLL3 mutation + TMB-H
MLL3 mutation + TMB-H
Non Small Cell Lung Cancer
NSCLC
PD-L1 inhib
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
MLL3 mutation + TMB-H
MLL3 mutation + TMB-H
Non Small Cell Lung Cancer
NSCLC
PD1 inhib + CTLA4 inhib
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
RET fusion
RET fusion
Lung Cancer
Lung Cancer
lenvatinib
Sensitive: B - Late Trials
IASLC-WCLC 2021 - 4 days
Sensitive: B - Late Trials
IASLC-WCLC 2021 - 4 days
KMT2D mutation + TMB-H
KMT2D mutation + TMB-H
Non Small Cell Lung Cancer
NSCLC
PD-L1 inhib
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
KRAS G12C
KRAS G12C
Lung Non-Squamous Non-Small Cell Cancer
Lung Non-Squamous Non-Small Cell Cancer
Immunotherapy
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
KMT2D mutation + TMB-H
KMT2D mutation + TMB-H
Non Small Cell Lung Cancer
NSCLC
PD1 inhib + CTLA4 inhib
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
Sensitive: B - Late Trials
IASLC-WCLC 2020 - 4 days
BRAF V600E
BRAF V600E
Glioblastoma
GBM
trametinib + dabrafenib
Sensitive: C1 - Off-label
Curr Probl Cancer - 4 days
Sensitive: C1 - Off-label
Curr Probl Cancer - 4 days
EGFR T790M
EGFR T790M
Non Small Cell Lung Cancer
NSCLC
olmutinib
Sensitive: C2 – Inclusion Criteria
Cancer - 4 days
Sensitive: C2 – Inclusion Criteria
Cancer - 4 days
TMB-H + PD-L1 overexpression
TMB-H + PD-L1 overexpression
Non Small Cell Lung Cancer
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
TNB-H
TNB-H
Non Small Cell Lung Cancer
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
PD-L1 overexpression
PD-L1 overexpression
Peripheral T-cell Lymphoma
Peripheral T-cell Lymphoma
GB226
Sensitive: C3 – Early Trials
J Hematol Oncol - 4 days
Sensitive: C3 – Early Trials
J Hematol Oncol - 4 days
ALK rearrangement
ALK rearrangement
Lung Adenocarcinoma
LUAD
Tyrosine kinase inhib
Sensitive: C3 – Early Trials
IASLC-WCLC 2020 - 4 days
Sensitive: C3 – Early Trials
IASLC-WCLC 2020 - 4 days
HER-2 amplification
HER-2 amplification
Non Small Cell Lung Cancer
NSCLC
SHR-1258 + rivoceranib
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
STK11 mutation
STK11 mutation
Non Small Cell Lung Cancer
NSCLC
APG-115
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
HER-2 G766V
HER-2 G766V
Non Small Cell Lung Cancer
NSCLC
lapatinib + SHR-1258
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
EGFR mutation
EGFR mutation
Lung Adenocarcinoma
LUAD
Tyrosine kinase inhib
Sensitive: C3 – Early Trials
IASLC-WCLC 2020 - 4 days
Sensitive: C3 – Early Trials
IASLC-WCLC 2020 - 4 days
EGFR mutation + KRAS mutation
EGFR mutation + KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
Lung Non-Squamous Non-Small Cell Cancer
Tyrosine kinase inhib
Sensitive: C3 – Early Trials
IASLC-WCLC 2020 - 4 days
Sensitive: C3 – Early Trials
IASLC-WCLC 2020 - 4 days
HER-2 A775_G776insYVMA
HER-2 A775_G776insYVMA
Non Small Cell Lung Cancer
NSCLC
SHR-1258 + rivoceranib
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
Sensitive: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
PRDX1 exon 5 - NTRK1 exon 12 fusion
PRDX1 exon 5 - NTRK1 exon 12 fusion
Lung Adenocarcinoma
LUAD
Trk inhib
Sensitive: C4 – Case Studies
IASLC-WCLC 2020 - 4 days
Sensitive: C4 – Case Studies
IASLC-WCLC 2020 - 4 days
EGFR exon 20 insertion
EGFR exon 20 insertion
Non Small Cell Lung Cancer
NSCLC
Tyrosine kinase inhib
Resistant: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
Resistant: C3 – Early Trials
IASLC-WCLC 2021 - 4 days
EGFR overexpression
EGFR overexpression
Osteosarcoma
Osteosarcoma
gemcitabine
Resistant: D – Preclinical
Acta Biochim Biophys Sin (Shanghai) - 4 days
Resistant: D – Preclinical
Acta Biochim Biophys Sin (Shanghai) - 4 days
No biomarker
No biomarker
Urothelial Cancer
Urothelial Cancer
avelumab
Sensitive: A1 - Approval
Cision - 5 days
Sensitive: A1 - Approval
Cision - 5 days
MSI-H/dMMR
MSI-H/dMMR
Colorectal Cancer
CRC
pembrolizumab
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
MSI-H/dMMR
MSI-H/dMMR
Colorectal Cancer
CRC
nivolumab + ipilimumab
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
RET fusion
RET fusion
Thyroid Gland Carcinoma
Thyroid Gland Carcinoma
pralsetinib
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
BRCA2 mutation
BRCA2 mutation
Pancreatic Cancer
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
BRCA1 mutation
BRCA1 mutation
Pancreatic Cancer
Pancreatic Cancer
olaparib
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
Sensitive: A1 - Approval
ASCO-GI 2021 - 5 days
IDH1 mutation
IDH1 mutation
Cholangiocarcinoma
Cholangiocarcinoma
ivosidenib
Sensitive: A2 - Guideline
ASCO-GI 2021 - 5 days
Sensitive: A2 - Guideline
ASCO-GI 2021 - 5 days
HER-2 amplification
HER-2 amplification
Colorectal Cancer
CRC
trastuzumab + pertuzumab
Sensitive: A2 - Guideline
ASCO-GI 2021 - 5 days
Sensitive: A2 - Guideline
ASCO-GI 2021 - 5 days
EGFR mutation
EGFR mutation
Lung Adenocarcinoma
LUAD
gefitinib
Sensitive: B - Late Trials
BMC Cancer - 5 days
Sensitive: B - Late Trials
BMC Cancer - 5 days
BRAF mutation
BRAF mutation
Colorectal Cancer
CRC
ziv-aflibercept IV
Sensitive: B - Late Trials
ASCO-GI 2021 - 5 days
Sensitive: B - Late Trials
ASCO-GI 2021 - 5 days
BRAF mutation
BRAF mutation
Colorectal Cancer
CRC
bevacizumab
Sensitive: B - Late Trials
ASCO-GI 2021 - 5 days
Sensitive: B - Late Trials
ASCO-GI 2021 - 5 days
No biomarker
No biomarker
Merkel Cell Carcinoma
Merkel Cell Carcinoma
AST-008
Sensitive: B - Late Trials
Exicure Press Release - 5 days
Sensitive: B - Late Trials
Exicure Press Release - 5 days
EGFR mutation
EGFR mutation
Lung Adenocarcinoma
LUAD
afatinib
Sensitive: C1 - Off-label
BMC Cancer - 5 days
Sensitive: C1 - Off-label
BMC Cancer - 5 days
RET fusion
RET fusion
Pancreatic Cancer
Pancreatic Cancer
pralsetinib
Sensitive: C1 - Off-label
ASCO-GI 2021 - 5 days
Sensitive: C1 - Off-label
ASCO-GI 2021 - 5 days
RET fusion
RET fusion
Cholangiocarcinoma
Cholangiocarcinoma
pralsetinib
Sensitive: C1 - Off-label
ASCO-GI 2021 - 5 days
Sensitive: C1 - Off-label
ASCO-GI 2021 - 5 days
HER-2 overexpression
HER-2 overexpression
Gastric Cancer
Gastric Cancer
ASLAN001
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2021 - 5 days
Sensitive: C2 – Inclusion Criteria
ASCO-GI 2021 - 5 days